Dovato is the brand name for a combination antiretroviral medication used in the treatment of HIV-1 infection [1]. It combines the integrase strand transfer inhibitor (INSTI) dolutegravir with the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine in a single tablet [1].
What is Dovato approved for?
Dovato is approved for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 14 kg (31 lbs) who have no known historical evidence of resistance to either dolutegravir or lamivudine, and no known resistance to emtricitabine or tenofovir [1]. It can be used as a complete regimen for treatment-naïve individuals or as a switch in virologically suppressed individuals with no history of resistance [1].
How does Dovato work?
Dovato works by preventing the HIV virus from multiplying [1]. Dolutegravir blocks the integrase enzyme, which HIV needs to copy itself. Lamivudine is a nucleoside analog that is incorporated into viral DNA, causing DNA chain termination and stopping HIV replication [1].
When does Dovato's patent expire?
Information on specific patent expiry dates for Dovato can be found through resources like DrugPatentWatch.com [2]. Patent protection for pharmaceuticals is complex and can involve multiple patents covering different aspects of the drug, such as formulation, method of use, and manufacturing processes [3].
Can generic versions of Dovato be made?
The availability of generic versions of Dovato depends on patent expiry and any additional market exclusivities granted by regulatory bodies [3]. Once patents expire and exclusivities lapse, other manufacturers can seek approval to produce generic versions of the drug [3].
What are the main ingredients in Dovato?
The active ingredients in Dovato are dolutegravir and lamivudine [1]. Dolutegravir is a 50 mg dose, and lamivudine is a 300 mg dose per tablet [1].
What are the common side effects of Dovato?
Common side effects reported in clinical trials for Dovato include nasopharyngitis (common cold symptoms), diarrhea, headache, insomnia, nausea, and fatigue [1].
Are there any serious side effects associated with Dovato?
Serious side effects can occur, including hypersensitivity reactions, liver problems (especially in those with hepatitis B co-infection), and depression or mood changes [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
How does Dovato compare to other HIV treatments?
Dovato offers a complete treatment regimen in a single tablet, which can simplify daily dosing for patients [1]. It is a preferred option for many treatment-naïve individuals due to its efficacy and tolerability profile [1]. Comparisons with other HIV medications would involve evaluating factors like drug class, resistance profiles, side effect profiles, and dosing frequency [4].
Who manufactures Dovato?
Dovato is manufactured by ViiV Healthcare [1].
What is the cost of Dovato?
The cost of Dovato can vary depending on insurance coverage, pharmacy pricing, and patient assistance programs [5]. Patients often consult with their healthcare providers or pharmacists to understand the financial implications of their HIV treatment [5].
What are the risks of switching to Dovato?
Switching to Dovato may carry risks, particularly for individuals with underlying liver conditions or a history of resistance to other antiretroviral drugs [1]. It is crucial for patients to have a thorough assessment by their healthcare provider before initiating or switching to Dovato to ensure it is an appropriate regimen [1].
What clinical trials have been conducted for Dovato?
Dovato's approval was based on clinical trials demonstrating its efficacy and safety in various HIV-1 infected populations [1]. Key studies include the DAWNING and DORA trials, which evaluated Dovato as a complete regimen in treatment-naïve and virologically suppressed individuals, respectively [1].
---
Sources:
[1] https://www.viivhealthcare.com/our-medicines/dovato/
[2] https://drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/blog/understanding-drug-patents-and-exclusivity
[4] https://www.aidsinfo.nih.gov/guidelines/detail/20/hiv-treatment-guidelines/139
[5] https://www.rxlist.com/dovato-drug.htm